Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
Hamid Rahmani, Effat Davoudi-Monfared, Anahid Nourian, Morteza Nabiee, Setayesh Sadeghi, Hossein Khalili, Ladan Abbasian, Fereshteh Ghiasvand, Arash Seifi, Malihe Hasannezhad, Sara Ghaderkhani, Mostafa Mohammadi, Mir Saeed Yekaninejad
Topics & Concepts
MedicineAtazanavirRitonavirHydroxychloroquineLopinavirIntensive care unitInternal medicinePneumoniaAdverse effectCoronavirus disease 2019 (COVID-19)AnesthesiaDiseaseViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyInfectious disease (medical specialty)ImmunologyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchPharmacological Receptor Mechanisms and Effects